Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Natera, Inc. NTRA
$50.82
-$0.79 (-1.55%)
На 18:00, 12 мая 2023
+60.04%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
5956848730.00000000
-
week52high
59.75
-
week52low
27.35
-
Revenue
820222000
-
P/E TTM
-10
-
Beta
1.21868500
-
EPS
-5.53000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 20:00
Описание компании
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | Overweight | 18 авг 2022 г. |
| JP Morgan | Overweight | Overweight | 05 авг 2022 г. |
| Piper Sandler | Overweight | Overweight | 16 мая 2022 г. |
| Morgan Stanley | Overweight | Overweight | 09 мая 2022 г. |
| Stephens & Co. | Overweight | 25 апр 2022 г. | |
| Credit Suisse | Outperform | 25 авг 2022 г. | |
| Credit Suisse | Outperform | Outperform | 14 ноя 2022 г. |
| Raymond James | Outperform | Market Perform | 18 янв 2023 г. |
| Piper Sandler | Overweight | Overweight | 17 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Brophy Michael Burkes | D | 49664 | 4152 | 01 февр 2023 г. |
| Brophy Michael Burkes | D | 53816 | 10413 | 01 февр 2023 г. |
| Brophy Michael Burkes | D | 64229 | 4761 | 01 февр 2023 г. |
| Brophy Michael Burkes | D | 68990 | 35000 | 31 янв 2023 г. |
| Brophy Michael Burkes | D | 103990 | 1509 | 30 янв 2023 г. |
| Brophy Michael Burkes | D | 105499 | 47188 | 30 янв 2023 г. |
| Rabinowitz Matthew | A | 152643 | 152643 | 27 янв 2023 г. |
| Brophy Michael Burkes | A | 152687 | 49664 | 27 янв 2023 г. |
| Schueren Robert Alan | A | 24091 | 19865 | 27 янв 2023 г. |
| RABINOWITZ DANIEL | A | 179893 | 31040 | 27 янв 2023 г. |
Новостная лента
Natera, Inc. (NTRA) Q1 2023 Earnings Call Transcript
Seeking Alpha
09 мая 2023 г. в 23:07
Natera, Inc. (NASDAQ:NTRA ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Steven Chapman - Chief Executive Officer Michael Brophy - Chief Financial Officer Alexey Aleshin - Chief Medical Officer John Fesko - Chief Business Officer Conference Call Participants Tejas Savant - Morgan Stanley Puneet Souda - SVB Securities Thomas Peterson - Baird Daniel Brennan - TD Cowen Alexander Nowak - Craig-Hallum Operator Hello. Welcome to Natera's 2023 First Quarter Financial Results Conference Call.
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
09 мая 2023 г. в 19:52
Natera (NTRA) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to loss of $1.45 per share a year ago.
Natera Is There For A Long Game (Technical Analysis)
Seeking Alpha
02 мар 2023 г. в 19:01
Cutting the cash burn and other operational expenses should bring back Natera, Inc. financial health. Natera produced in 2022 loads of peer-reviewed ammunition for winning more and more market share in women's health, oncology, and organ transplant.
Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
28 февр 2023 г. в 21:50
Natera (NTRA) delivered earnings and revenue surprises of 2.14% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Natera (NTRA) This Earnings Season?
Zacks Investment Research
27 февр 2023 г. в 09:47
Natera (NTRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.